Latest breakthroughs in cancer research, treatment, and prevention
606 artigos
A phase II trial tests whether sunitinib retains activity in metastatic renal cell carcinoma after first-line immunotherapy resistance.
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
A Lancet Healthy Longevity editorial calls for systemic elevation of cancer survivorship care as a public health and longevity priority.
A newly discovered molecular pathway explains why many colorectal cancers resist immunotherapy — and points to a druggable target.
A landmark Cell study reveals cells transfer cytoplasmic DNA fragments to neighbors via nanotubes, stably reshaping recipient genomes.
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
Adding an autophagy inhibitor to anlotinib plus PD-1 blockade dramatically reshapes the tumor microenvironment in NSCLC models.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-γ/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
Cancer cells exploit cholesterol biosynthesis to keep PD-L1 high, silencing T cells — and blocking this pathway restores anti-tumor immunity.
Scientists uncover how SCRN1 blocks ferroptosis in liver cancer, revealing new targets for treating drug-resistant hepatocellular carcinoma.
Synthetic super-enhancers hijack glioblastoma's own regulatory circuits to trigger precise, tumor-only cell death and durable immune memory.
New review reveals how HER2 reshapes the tumor immune environment — and why beating it requires more than blocking the oncogene.
